Company attributes
Other attributes
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
Sierra Oncology is a publicly traded, clinical stage drug development company based in Vancouver, British Colombia. It is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology.
The company's lead product candidate is momelotinib, a potent, selective, and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing a range of anemia benefits, including eliminating or reducing the need for frequent blood transfusions as well as spleen and constitutional symptom control. Momelotinib has been investigated in two completed Phase 3 clinical trials for the treatment of myelofibrosis. The product was acquired by Sierra Oncology from Gilead.
The company is also advancing two other products, SRA737 and SRA141. SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1). Chk1 is a key regulator of cell cycle progression and the DDR (DNA Damage Response) damage response. Targeted inhibition of Chk1 by SRA737 may be synthetically lethal to cancer cells with elevated intrinsic replication stress and have utility as a monotherapy in a range of tumor indications.
SRA737 is being evaluated in two Phase 1/2 clinical trials in patients with advanced cancer, one study as a monotherapy and the other study as a combination therapy with subtherapeutic, low dose gemcitabine. Sierra is also conducting pre-clinical research evaluating SRA737 in combination with other DDR-targeted agents, including poly ADP ribose polymerase (PARP) inhibitors, as well as with immuno-oncology therapeutics.
SRA141 on the other hand, is a potent, selective, and orally bioavailable small molecule inhibitor of cell division cycle 7 kinase (Cdc7). It is a key regulator of DNA replication and is involved in the DDR network. An Investigational New Drug (IND) application is being prepared for submission in order to begin clinical trials.
